Firebrick Pharma Ltd FRE
Trading Information
- Previous Close Price
- A$0.03
- Day Range
- A$0.03–0.03
- 52-Week Range
- A$0.02–0.07
- Bid/Ask
- A$0.03 / A$0.03
- Shares Outstanding
- 287.20M
- Market Cap
- A$8.04M
- Volume/Avg
- 45,731 / 165,673
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 64.75
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Firebrick Pharma Ltd is engaged in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine AE brand, with its anchor product being Nasodine AE Nasal Spray, which is in the commercialization phase and launched in several markets. The company operates in one business segment, namely the development and commercialization of nasal sprays. Geographically it operates in Asia which generates the maximum revenue, followed by North America, Europe and others.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Small Core
- Total Number of Employees
- —
- Website
- https://www.firebrickpharma.com
Valuation
|
Metric
|
FRE
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.58 |
Price/Sales | 64.75 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
FRE
|
|---|---|
Quick Ratio | 4.31 |
Current Ratio | 6.32 |
Interest Coverage | — |
Quick Ratio
FRE
Profitability
|
Metric
|
FRE
|
|---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
FRE
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|#HXSnS%Z | LOCK|Q? | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|s>h$nK@ | LOCK|pq^ | $623B | |||
| AbbVie Inc
ABBV
| LOCK|$$?@%@ | LOCK|Yd | $480B | |||
| Merck & Co Inc
MRK
| LOCK|CHP#$yd | LOCK|Yvq | $352B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|>&@$lM> | LOCK|?J | $346B | |||
| Novartis AG ADR
NVS
| LOCK|xkM#&PQB | LOCK|>> | $274B | |||
| AstraZeneca PLC
AZN
| LOCK|!&k?Q?! | LOCK|lrt | $251B | |||
| Amgen Inc
AMGN
| LOCK|V?M?&B< | LOCK|?K | $223B | |||
| Gilead Sciences Inc
GILD
| LOCK|h^!WDH% | LOCK|S&C | $182B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|LnRVBbt | LOCK|PF | $169B |
United States